Status:
COMPLETED
An Exploratory Clinical Study to Assess Safety, Efficacy and In-Use Tolerability of Three Different Hair Growth Products in Patients With Mild to Moderate Androgenic Alopecia (Grade I to III)
Lead Sponsor:
NovoBliss Research Pvt Ltd
Collaborating Sponsors:
Zywie Ventures Privated Ltd
Conditions:
Androgenic Alopecia
Eligibility:
All Genders
25-45 years
Phase:
NA
Brief Summary
This is an exploratory, prospective, three-arm, interventional, comparative, randomized, double-blind, placebo-controlled, safety, efficacy and in-use tolerability study of hair growth products in the...
Detailed Description
A total of up to 54 patients (18 patients/arm) preferably equal number of male and female will be enrolled to ensure a total of 45 patients (15 patients/ arm) to complete the study. Additional arm 4, ...
Eligibility Criteria
Inclusion
- Age: 25 to 45 years and above (both inclusive) at the time of consent.
- Sex: Males and non-pregnant/non-lactating females (preferably equal number of males and females).
- Females of childbearing potential must have a self-reported negative urine pregnancy.
- Subject is in good general health as determined by the Investigator on the basis of medical history.
- Patients having mild to moderate androgenic alopecia (Grade I to III) during clinical study and grade will be evaluated by the dermatologist by using Norwood-Hamilton classification and Ludwig pattern scale for female.
- Female with 40-50 counts and male with 25 -30 counts of hair fall at screening.
- Subject is able to remain on stable doses of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study.
- If the subject is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device/injection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation.
- Patients are willing to give written informed consent and are willing to follow the study procedure.
- Patients who commit not to use any other medicated/ prescription shampoos/hair care products (containing Minoxidil), any other hair growth products or hair colour or dye, other than the test products for the entire duration of the study.
- Willing to use test products throughout the study period.
- Subject is willing and able to follow and allow study staff to performed study test methods.
- Subject is willing and able to follow the study directions, to participate in the study, returning for all specified visits.
- Subject must be able to understand and provide written informed consent to participate in the study.
Exclusion
- Subject have history of severe hair fall due to any clinically significant problems like anaemia, thyroid problems.
- Subject have history of any dermatological condition of the scalp other than hair loss and dandruff.
- Subject have history of any prior hair growth procedures (e.g. hair transplant or laser).
- Subject who had taken topical treatment of hair loss for at least 4 weeks.
- Subject who had taken any systemic treatment for at least 3 months.
- History of alcohol or drug addiction.
- Subject having history or resent condition of irritated or visibly inflamed scalp or severe scalp disease.
- Subject having history or present condition of an allergic response to any cosmetic products, any other condition which could warrant exclusion from the study.
- Pregnant or breast feeding or planning to become pregnant during the study period.
- History of chronic illness which may influence the cutaneous state.
- Subject have participated any clinical research study related to hair care products.
- Subject have history of mastectomy for cancer involving removal of lymph nodes within the past year, or treatment of any type of cancer within the last 6 months.
Key Trial Info
Start Date :
June 30 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2025
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT06556056
Start Date
June 30 2024
End Date
June 30 2025
Last Update
September 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NovoBliss Research Private Limited
Ahmedabad, Gujarat, India, 382481